Ansuvimab
drugOn this page
Also known as Ansuvimab zyklAnsuvimab-zyklEVB-114EVB114EbangaEboV mAb114MAB-114Mab114
Summary
Ansuvimab (CHEMBL4594388) is an approved antibody (ATC J06BD04); indicated across 2 conditions including ebola hemorrhagic fever.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: J06BD04
- Indications: 2 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594388 |
| Name | Ansuvimab |
| Type | Antibody |
| Max phase | 4 |
| ATC | J06BD04 |
Also known as: Ansuvimab, Ansuvimab zykl, Ansuvimab-zykl, EVB-114, EVB114, Ebanga, EboV mAb114, MAB-114, Mab114, MAB114, ANSUVIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Ebola hemorrhagic fever | 4 | MONDO:0005737 | EFO:0007243 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03719586 | PHASE2/PHASE3 | COMPLETED | Investigational Therapeutics for the Treatment of People With Ebola Virus Disease |
| NCT04822376 | PHASE2 | UNKNOWN | Prophylaxis Vaccine Antibodies Ebola |
| NCT03478891 | PHASE1 | COMPLETED | Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults |
| NCT05067166 | Not specified | AVAILABLE | Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: Ebola hemorrhagic fever